stockrowJazz Pharmaceuticals PLC
JAZZ Healthcare Biotechnology
Jazz Pharmaceuticals PLC’s revenue for fiscal 2025 (year ended December 2025) was $4.3 billion, up 4.88% from fiscal 2024.
- Revenue
- +10.4%
- EPS
- −280.5%
- Free cash flow
- −60.4%
- Total debt
- +3.88%
Quarter to September 2026, against a year earlier
Follow JAZZ
Alert me
Jazz Pharmaceuticals PLC (JAZZ) Total debt
Jazz Pharmaceuticals PLC's total debt at the end of fiscal 2025 was $5.4B, down 12.3% from $6.1B in fiscal 2024. At the end of the quarter to 30 September 2026 it was $5.6B. Over the past ten years it has ranged from $1.2B (fiscal 2015) to $6.1B (fiscal 2024); the current reading is higher than 64% of that period. Jazz Pharmaceuticals PLC ranks 2nd of 569 Biotechnology companies by total debt.
Total debt, annual
Embed this chart
Annual newest first
| Period | Total debt | Change |
|---|---|---|
| FY2025 | $5.4B | (12.28%) |
| FY2024 | $6.1B | 6.93% |
| FY2023 | $5.7B | (0.20%) |
| FY2022 | $5.7B | (5.38%) |
| FY2021 | $6.0B | 188.80% |
| FY2020 | $2.1B | 30.34% |
| FY2019 | $1.6B | 0.68% |
| FY2018 | $1.6B | 0.97% |
| FY2017 | $1.6B | (22.10%) |
| FY2016 | $2.0B | 70.78% |
Quarterly newest first
| Period | Total debt | Change |
|---|---|---|
| Sep 2026 | $5.6B | 27.99% |
| Jun 2026 | $4.4B | (18.74%) |
| Mar 2026 | $5.4B | (0.07%) |
| Dec 2025 | $5.4B | (0.05%) |
| 43 more quarters | Free account |
Against its own ten years
Total debt against peers
| Company | Total debt |
|---|---|
| JAZZ Jazz Pharmaceuticals PLC | $5.6B |
| BMRN BioMarin Pharmaceutical Inc. compare | $4.2B |
| HALO Halozyme Therapeutics, Inc. compare | $3.3B |
| BBIO BridgeBio Pharma, Inc. compare | $1.9B |
| ASND Ascendis Pharma A/S compare | $523.3M |
| TECH Bio-Techne Corp compare | $200.0M |
| EXEL Exelixis, Inc. compare | $191.0M |
| SMMT Summit Therapeutics PLC compare | $100.0M |
| KYMR Kymera Therapeutics, Inc. compare | $602.0K |
What Total debt is
Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.
Long Term Debt (Total) + Current Part of Debt
More on JAZZ
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement